Get the Stockscreener App
7.30
2.24%
0.16
After Hours:
7.29
-0.010
-0.14%
Immunitybio Inc stock is traded at $7.30, with a volume of 14.05M.
It is up +2.24% in the last 24 hours and down -30.08% over the past month.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
See More
Previous Close:
$7.14
Open:
$6.89
24h Volume:
14.05M
Relative Volume:
0.38
Market Cap:
$7.54B
Revenue:
$113.29M
Net Income/Loss:
$-351.47M
P/E Ratio:
-18.73
EPS:
-0.3898
Net Cash Flow:
$-309.19M
1W Performance:
-1.08%
1M Performance:
-30.08%
6M Performance:
+192.00%
1Y Performance:
+139.34%
1-Day Range:
$6.88
$7.35
1-Week Range:
$6.57
$7.85
52-Week Range:
$1.83
$12.43
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
7.30 | 7.37B | 113.29M | -351.47M | -309.19M | -0.3898 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 113.62B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 82.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.12B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 43.60B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.54B | 606.42M | -1.28B | -997.58M | -6.403 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-26 | Resumed | BTIG Research | Buy |
| May-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-06-25 | Initiated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | BTIG Research | Buy |
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
View All
Immunitybio Inc Stock (IBRX) Latest News
NASDAQ: IBRX: Kessler Topaz Meltzer & Check, LLP Announces - GlobeNewswire
IMMUNITYBIO, INC. (IBRX) SHAREHOLDER ALERT Bernstein - GlobeNewswire
ImmunityBio Shareholder Alert: ClaimsFiler Reminds - GlobeNewswire
IBRX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of ... - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming DeadlinesIBRX - PR Newswire
ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman - PR Newswire
Jim Cramer on ImmunityBio: "I would encourage you to own it, provided you don’t own any other spec" - MSN
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed By the Firm - morningstar.com
ROSEN, A LEADING LAW FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before ... - Bluefield Daily Telegraph
ROSEN, A LEADING LAW FIRM, Encourages ImmunityBio, Inc. - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire
IBRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ImmunityBio, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
IBRX Investor Alert: ImmunityBio Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Company Allegedly Violated FDA Drug Rules: Levi & Korsinsky - PR Newswire
IBRX stock notches strongest quarter ever — but these 2 smaller biotech plays ran even hotter - MSN
ImmunityBio (IBRX) Rallies 15% as Firm Raises $100M For Global Expansion - Insider Monkey
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Morningstar
IBRX Stock Notches Strongest Quarter Ever — But These 2 Smaller Biotech Plays Ran Even Hotter - Stocktwits
ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - GlobeNewswire Inc.
10 Stocks Dominating Today’s Market Surge: ImmunityBio, Alkermes, and More - Insider Monkey
Is It Time To Reassess ImmunityBio (IBRX) After Its Recent Volatile Share Price Swings - Yahoo Finance
ImmunityBio, Inc. (IBRX) Faces Securities Class Action Amid FDA Warning Regarding Unsupported Cancer Treatment Claims, $2 Billion Market Capitalization Wiped Out -- Hagens Berman - GlobeNewswire Inc.
Bronstein, Gewirtz & Grossman, LLC Encourages ImmunityBio, Inc. (IBRX) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
ImmunityBio (NASDAQ:IBRX) Shares Up 15.2%What's Next? - MarketBeat
Investors Seek Lead in ImmunityBio Class Action Lawsuit - National Today
Dunkirk pharma plant prepares to hire 100, kick off production - The Business Journals
INVESTOR ALERT: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit - PR Newswire
Investors Warned of Large Losses in ImmunityBio Stock - National Today
Why Are ImmunityBio Shares Rising Today? - Benzinga
Jim Cramer on ImmunityBio: “I Would Encourage You to Own It, Provided You Don’t Own Any Other Spec” - Yahoo Finance
Anktiva Gains Ground in Global Cancer Treatment Strategy - StocksToTrade
ImmunityBio strengthens balance sheet to fund Anktiva commercialization - The Pharma Letter
Law Offices of Frank R. Cruz Encourages ImmunityBio, Inc. (IBRX) Shareholders To Inquire About Securities Fraud Class Action - Business Wire
ImmunityBio plunges after getting FDA warning on cancer drug - msn.com
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against ImmunityBio, Inc. (IBRX) - TMX Newsfile
ImmunityBio Inc. (IBRX) Receives FDA Warning Letter Over Cancer Therapy Claims in Advertisement - Insider Monkey
ImmunityBio Secures Major Milestone With ANKTIVA in Asia-Pacific Expansion - timothysykes.com
ImmunityBio Bolsters Balance Sheet With New Financing Moves - TipRanks
IBRX Stock Rises 8% As $100M Financing Boosts Balance Sheet - Stocktwits
ImmunityBio adds $75M under Oberland deal (IBRX:NASDAQ) - Seeking Alpha
IBRX Shareholder Alert: May 26, 2026 Lead Plaintiff Deadline in ImmunityBio, Inc. Securities Class Action Lawsuit — The Gross Law Firm - morningstar.com
ImmunityBio stock surges on $100M financing deal - Investing.com
ImmunityBio Secures $75 Million Through Second Amendment to Revenue Interest Agreement - TradingView
ImmunityBio (NASDAQ: IBRX) adds $75M non-dilutive cash and converts $25M debt - Stock Titan
IMMUNITYBIO, INC. (IBRX) INVESTOR ALERT Investors With - GlobeNewswire
ImmunityBio secures $75M funding, converts $25M debt to equity - Investing.com
ImmunityBio strengthens balance sheet with $100 million of financing transactions including $75 million of non-dilutive financing to support global expansion and advancement of broader immunotherapy pipeline - MarketScreener
Immunitybio Strengthens Balance Sheet With $100 Million Of Financing Transactions Including $75 Million Of Non-Dilutive Financing To Support Global Expansion And Advancement Of Broader Immunotherapy Pipeline - TradingView
ImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million of Non-Dilutive Financing to Support Global Expansion and Advancement of Broader Immunotherapy Pipeline - Business Wire
IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit – Investors With Losses May Seek to Lead the Class Action After Soon-Shiong Allegedly Overstated ANKTIVA Efficacy: Levi & Korsinsky - TipRanks
FDA Warns Biotech Firm Over Cancer Drug Claims - Infectious Disease Advisor
ImmunityBio Hit with Class Action Lawsuit - National Today
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immunitybio Inc Stock (IBRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Selecky Christobel | Director |
Feb 23 '26 |
Option Exercise |
2.98 |
25,000 |
74,500 |
25,000 |
| Selecky Christobel | Director |
Feb 23 '26 |
Sale |
10.00 |
25,000 |
250,000 |
0 |
| Sachs David C. | Chief Financial Officer |
Feb 22 '26 |
Option Exercise |
0.00 |
40,650 |
0 |
320,825 |
| SOON-SHIONG PATRICK | See remarks |
Feb 22 '26 |
Option Exercise |
0.00 |
114,329 |
0 |
29,816,081 |
| LAUER REGAN J | Chief Accounting Officer |
Feb 22 '26 |
Option Exercise |
0.00 |
4,065 |
0 |
117,548 |
| Adcock Richard | CEO & President |
Feb 22 '26 |
Option Exercise |
0.00 |
152,439 |
0 |
637,904 |
| Simon Barry J. | Director |
Feb 22 '26 |
Option Exercise |
0.00 |
15,243 |
0 |
3,096,847 |
| Simon Barry J. | Director |
Feb 23 '26 |
Sale |
10.25 |
165,000 |
1,691,102 |
2,925,821 |
| Simon Barry J. | Director |
Feb 20 '26 |
Sale |
9.25 |
10,000 |
92,500 |
3,081,604 |
0.49%
1.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):